Kyntra Bio (NASDAQ:KYNB) Now Covered by Analysts at Rodman & Renshaw

Stock analysts at Rodman & Renshaw initiated coverage on shares of Kyntra Bio (NASDAQ:KYNB) in a report released on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Rodman & Renshaw’s price objective suggests a potential upside of 352.49% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Kyntra Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. HC Wainwright raised shares of Kyntra Bio to a “strong-buy” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Kyntra Bio Trading Down 1.2%

Shares of Kyntra Bio stock opened at $6.63 on Tuesday. Kyntra Bio has a twelve month low of $4.85 and a twelve month high of $12.60. The company has a market capitalization of $26.85 million, a PE ratio of 0.16 and a beta of 1.01. The business has a fifty day simple moving average of $7.00.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC acquired a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned approximately 0.68% of Kyntra Bio at the end of the most recent reporting period. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.